Once a futuristic concept, human digital twins (HDTs) are now reshaping biopharma by enabling in silico drug testing, virtual clinical trials, and personalized treatment strategies. These high-fidelity simulations integrate biological, clinical, and behavioral data to model individual responses to disease and therapy in real time. HDTs promise to reduce reliance on animal testing, improve clinical trial inclusivity, and support more proactive and equitable healthcare. As the technology advances, it is converging with digital biomarkers, wearables, and AI to create a dynamic ecosystem for anticipatory medicine. However, realizing their full potential will require robust data infrastructure, rigorous validation, and evolving regulatory frameworks. HDTs are not just digital replicas — they are the foundation for a smarter, more ethical, and deeply personalized future of healthcare.
From Concept to Reality
For decades, the idea of creating a virtual replica of a human being — one that mirrors not only their anatomy but also their physiology, behaviors, and health trajectory — existed largely in the realm of science fiction. Today, human digital twins (HDTs) are rapidly becoming a practical reality. These high-fidelity models combine real-time biological, clinical, and behavioral data to simulate and predict individual responses to disease, treatment, and lifestyle changes with remarkable precision.
What was once theoretical is now gaining traction across healthcare and biopharma. Leading research institutions and public health agencies have launched ambitious pilot programs to build and validate HDTs for specific organs and conditions. The National Institutes of Health (NIH), for instance, is actively developing digital heart models to better understand cardiovascular disease dynamics and predict treatment outcomes.1 Parallel efforts are unfolding in Europe, where researchers are exploring how HDTs can replace traditional animal models in early-stage drug development.2
This shift is not just about technological advancement; it reflects a broader transformation in how we approach health and medicine. HDTs promise to accelerate drug development, make clinical trials more efficient and inclusive, enable deeply personalized treatments, and enhance patient autonomy. Their rise signals a profound realignment in biopharma’s priorities: away from population-level generalizations and toward precision-guided care that is proactive, ethical, and patient-centered.
What Are Human Digital Twins?
HDTs are virtual constructs that replicate the physiological, anatomical, and sometimes behavioral characteristics of an individual in real time. Built on vast data sets and advanced computational frameworks, HDTs are designed not merely to describe but to simulate how a person’s body functions under different conditions, whether healthy, diseased, medicated, or stressed. At their core, they rely on multi-scale modeling to integrate biological processes from the molecular level to the organ and system level, enabling real-time physiological simulation and predictive analytics powered by artificial intelligence (AI) and machine learning algorithms.3,4
HDTs can take many forms depending on the application. Some are organ-specific, such as virtual models of the heart developed to study arrhythmias or to simulate cardiovascular responses to specific drugs or interventions.1 Others are disease-state models designed to capture the complex biological networks involved in cancer, diabetes, or neurodegenerative disorders, enabling researchers to test hypotheses and therapies in silico before moving to human trials.5 At the most advanced end of the spectrum are whole-body or systems-level twins that integrate diverse data sets — genomic, proteomic, biometric, behavioral, and environmental — into dynamic, individualized representations capable of simulating interactions across the entire body.6
The construction and utility of HDTs depend on several enabling technologies. The exponential growth of health-related big data, fueled by electronic health records, genomic sequencing, and real-world evidence, provides the raw material. Wearable biosensors and implantable devices contribute continuous streams of high-resolution physiological data. Cloud computing and edge AI — where data are processed closer to the source — enable real-time responsiveness and scalability, essential for applications in clinical settings or personal health management.4,6,7 Together, these advances make it possible to construct and update HDTs dynamically, setting the stage for truly personalized, predictive, and preventative medicine.
Applications in Biopharma R&D
HDTs are poised to redefine biopharmaceutical research and development by enabling more accurate simulations, minimizing trial-and-error experimentation, and accelerating time to market. Across the drug development pipeline, HDTs offer the potential to enhance efficiency, reduce risk, and ultimately deliver better therapies to patients faster.
Faster, Smarter Drug Discovery
The earliest stages of drug development are notoriously resource-intensive, with the overwhelming majority candidates failing before reaching clinical testing. HDTs can shift much of this discovery process from the lab bench to the computer, allowing researchers to simulate how new compounds interact with specific biological systems before conducting wet-lab experiments.8,9 These virtual environments can test thousands of molecular variations across a range of simulated patient profiles, helping scientists identify the most promising candidates more quickly and cost-effectively.
Beyond identifying potential leads, HDTs enable early prediction of off-target effects and toxicity risks, which are among the most common reasons for clinical failure. By modeling complex biological feedback loops and tissue-specific drug responses, HDTs support earlier go/no-go decisions and reduce reliance on animal models. This, in turn, improves return on investment and boosts the likelihood that a compound entering clinical trials will eventually reach the market.
Revolutionizing Clinical Trials
Perhaps the most immediate impact of HDTs lies in their ability to transform clinical trial design. One of the most innovative uses is the creation of simulated control arms, where digital twins stand in for real patients receiving placebo or standard-of-care treatment.10,11 This approach can significantly reduce the number of participants required, accelerate enrollment timelines, and address ethical concerns associated with withholding treatment from certain patients.
HDTs also improve trial stratification and endpoint prediction. By modeling likely responders based on genetics, disease progression, and other individualized variables, researchers can more effectively target trial recruitment and better predict efficacy across subgroups.12 Importantly, HDTs offer a way to address long-standing diversity gaps in clinical trials. Digital replicas of underrepresented populations can help assess differential drug responses and inform more inclusive study designs, even when those populations are difficult to recruit in practice.
Personalized Dosing and Drug Delivery
After a drug has been developed and approved, HDTs continue to add value by informing personalized treatment strategies. Using individualized models that account for factors such as metabolic rate, organ function, age, comorbidities, and even circadian biology, HDTs can simulate how a specific patient will process and respond to a given dose of medication.4,13 This has implications for minimizing adverse events, optimizing efficacy, and supporting adaptive dosing strategies in complex therapeutic areas like oncology or autoimmune disease.
Moreover, HDTs can be used to model long-term treatment effects and disease progression over time, enabling proactive adjustments to therapy before problems arise. By continuously integrating real-world data, HDTs offer a dynamic, living framework for treatment planning that moves beyond population averages toward truly individualized care.
From Patients to People: Human-Centric Medicine
HDTs are not only revolutionizing how drugs are developed — they are also transforming the role of the patient in healthcare. By translating complex biological and behavioral data into personalized simulations, HDTs allow medicine to move beyond reactive treatment and toward proactive, individualized care. The result is a more human-centered model of healthcare, where people are understood not just as patients with conditions, but as dynamic individuals with unique physiological profiles, lifestyles, and values.
Preventive and Predictive Care
One of the most promising applications of HDTs lies in their ability to detect signs of disease or dysfunction before they become clinically apparent. When connected to real-time data sources, such as wearable sensors, electronic health records, and environmental data, HDTs can serve as continuously updated models of a person’s health status. These models can generate alerts when early indicators of disease onset or adverse drug reactions emerge, giving clinicians the opportunity to intervene sooner.3,6
This predictive capacity opens the door to what could become a new standard of preventive care: the digital annual checkup. Instead of relying on intermittent physical exams and static lab results, clinicians could consult a patient's digital twin to assess organ health, metabolic shifts, and risk trajectories over time. This shift would allow for far more nuanced, longitudinal insights into a patient’s health and provide tailored recommendations for prevention and early intervention.
Empowering the Patient
As HDTs become more accessible and interactive, they also offer a unique opportunity to engage patients as active participants in their own care. Unlike traditional health records, which are often opaque and passive, HDTs can serve as dynamic, visual, and intuitive interfaces that help people understand how their behaviors, environments, and preferences influence their health outcomes.14 In this paradigm, patients become co-modelers able to see how changes in diet, exercise, sleep, or medication adherence might impact their future health trajectory.
This level of transparency and personalization has significant implications for digital health literacy. As users interact with their digital twins, they gain a clearer sense of cause and effect, which can foster greater accountability, adherence, and trust in medical recommendations. Over time, HDTs could serve not just as diagnostic or predictive tools, but as digital companions that help individuals navigate complex healthcare decisions with greater confidence and control.
Ethical Advantages and Challenges
As HDTs become increasingly integrated into biopharma and healthcare, they raise important ethical questions, alongside offering opportunities to address long-standing moral dilemmas in biomedical research. From replacing animal testing to enabling safer study of vulnerable populations, HDTs are positioned to advance not only scientific progress but also the ethical foundations of medical innovation. However, this promise is accompanied by new responsibilities around data governance, representation, and dual-use risk.
Reducing Animal Testing
One of the clearest ethical benefits of HDTs is their potential to reduce or replace the use of animals in drug development. Early-stage testing often relies on animal models to predict human pharmacology, despite well-documented limitations in translating findings across species. HDTs offer a powerful alternative, enabling early in silico evaluation of toxicity, metabolism, and efficacy in models that more accurately reflect human biology.15 These simulations can help narrow down candidates before animal or human testing is even considered, thus reducing the overall need for in vivo experimentation.
This shift is gaining institutional support. Research advocacy groups, regulatory bodies, and funding agencies are increasingly promoting non-animal alternatives, particularly where human-relevant models can offer superior translational value. Recent initiatives focused on accelerating ethical research approaches have highlighted HDTs as a cornerstone of the future non-animal scientific toolbox.2 As confidence in their predictive capabilities grows, HDTs could help redefine regulatory expectations for preclinical testing and accelerate the transition to more humane and scientifically robust development pipelines.
Human Research Ethics
Beyond animals, HDTs offer new ways to navigate the ethical complexities of studying high-risk or vulnerable human populations. In areas such as pediatrics, pregnancy, and rare disease, direct experimentation can be difficult or ethically constrained. HDTs enable simulation-based exploration of drug effects, disease progression, and intervention strategies without exposing real individuals to risk. This opens new avenues for innovation in spaces that have historically been under-researched due to ethical barriers.
At the same time, the emergence of HDTs brings with it serious concerns around consent, data privacy, and dual-use potential. A highly detailed model of an individual capable of simulating their health trajectory raises questions about ownership, accessibility, and potential misuse. Could digital twins be used to discriminate, manipulate, or exploit individuals in unintended ways? Addressing these risks will require comprehensive governance frameworks, including standards for data stewardship, model validation, and transparency in how simulations are built and used.11,12 As with any powerful technology, the ethical trajectory of HDTs will depend on how intentionally and inclusively they are developed and deployed.
Technical and Regulatory Considerations
While the potential of HDTs is immense, realizing their full impact requires overcoming substantial technical and regulatory hurdles. Building a digital replica of a human being that is sufficiently accurate, adaptable, and secure demands infrastructure and oversight frameworks that do not yet exist at scale. Interoperability, standardization, and trust are foundational challenges that must be addressed in tandem with the development of the models themselves.
A primary technical barrier is the need for seamless integration of diverse data types. HDTs rely on a complex array of inputs, ranging from genomic and biometric data to electronic health records and real-time sensor feeds. These sources are often fragmented across systems and formats, making interoperability a major obstacle. Robust, secure, and scalable infrastructure is required to collect, harmonize, and process this information dynamically, and to do so in a way that protects privacy and ensures data fidelity.4,7 Without such infrastructure, the creation of accurate and responsive digital twins remains out of reach for most healthcare systems.
Equally important is the need for rigorous validation. For HDTs to be trusted as clinical or regulatory tools, there must be clear standards for assessing their accuracy, reliability, and clinical relevance. What makes a twin “good enough” to inform a dosing decision, serve as a control arm in a trial, or stand in for animal testing? These questions are at the heart of emerging efforts to define quality benchmarks for HDTs, especially as their use shifts from research environments into regulated spaces.5
Regulatory bodies are beginning to engage with these questions. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both shown growing openness to the use of in silico models as part of drug development and approval pathways. The NIH’s digital heart twin project is one example of a government-backed initiative designed not just to advance science but also to inform evolving regulatory frameworks.1 At the same time, the incorporation of virtual patients into regulatory submissions raises new issues around model transparency, explainability, and liability, areas where policy guidance is still emerging.16 As HDTs gain ground, regulatory science will need to evolve in parallel to ensure that innovation is both safe and credible.
The Road Ahead: Integration and Impact
As HDTs continue to evolve, their integration with other emerging technologies promises to unlock even greater value across biopharma and healthcare. Rather than functioning as standalone simulations, HDTs are increasingly positioned at the nexus of a broader digital health ecosystem that includes digital biomarkers, digital therapeutics, generative AI, and real-time health monitoring systems. This convergence will not only enhance the sophistication of HDTs themselves but also enable more anticipatory, distributed, and equitable models of care delivery.6,8
Digital biomarkers derived from wearables and connected devices can feed directly into HDT platforms, providing continuous streams of individualized data that refine predictions and support adaptive interventions. Coupled with digital therapeutics — software-based treatments that can be tested and tailored using HDT simulations — this integration blurs the line between modeling and medicine. Meanwhile, generative AI is opening new possibilities for optimizing HDT construction by synthesizing missing data, refining simulation parameters, and generating patient-specific disease trajectories from limited inputs. These capabilities accelerate scalability and democratize access to precision tools previously available only in elite academic or clinical settings.
The shift from reactive to anticipatory healthcare becomes more tangible in this context. With HDTs functioning as living models that evolve alongside patients, healthcare systems can intervene earlier, personalize therapies more precisely, and monitor treatment responses in real time. This is not only a boon for chronic disease management and preventive care, but also a key enabler of decentralized and value-based care models.
Importantly, HDTs also offer tools for promoting global health equity. In settings with limited access to high-quality clinical infrastructure, HDT-based platforms could support remote diagnostics, simulate treatment strategies for underserved populations, and reduce dependence on local trial capacity. By leveraging cloud-based infrastructure and virtual modeling, digital twins make it possible to extend advanced clinical insights into regions historically excluded from cutting-edge research and care. In this way, HDTs hold the potential not just to transform individual treatment but to reshape the global distribution of medical innovation.
Developing a New Standard in Human-Centered Innovation
HDTs are not a replacement for the physical patient; they are a redefinition of how we understand, monitor, and treat human health. By integrating biological complexity with computational precision, HDTs offer a profound evolution in the practice of medicine. They allow us to simulate the future of a patient’s health, personalize care strategies with unprecedented accuracy, and test therapies before they are ever administered. In doing so, they reshape the very foundations of how drugs are discovered, trials are conducted, and patients are engaged.
To fully realize this potential, the biopharma and healthcare communities must commit to multidisciplinary collaboration across data science, systems biology, clinical medicine, regulatory affairs, and ethics. Scaling HDTs responsibly requires shared infrastructure, standards, and oversight, as well as investment in tools that ensure equity, transparency, and patient empowerment.
The future of precision medicine is no longer a distant aspiration. It is being modeled in silico, driven by ethical imperatives, and already delivering value across the healthcare continuum. Human digital twins mark a shift, not just toward better treatments but toward a smarter, more compassionate, and more proactive vision of care.
References
1. “Building digital twins and hearts.” National Heart, Lung, and Blood Institute. 8 Jan. 2025.
2. Gaffinet, Ben, et al. “Human Digital Twins: A systematic literature review and concept disambiguation for industry 5.0.” Computers in Industry. 166: 104230 (2025).
3. Shengli, Wei. “Is Human Digital Twin possible?” Computer Methods and Programs in Biomedicine Update. 1: 100014 (2021).
4. Lin, Yujia, et al. “Human digital twin: a survey.” Journal of Cloud Computing. 13: 131 (2024).
5. Venkatesh, Kaushik P, Gabriel Brito, and Maged N Kamel Boulos. “Health Digital Twins in Life Science and Health Care Innovation.” Annual Review of Pharmacology and Toxicology. 64:159–170 (2024).
6. “Human Digital Twins: Creating New Value Beyond the Constraints of the Real World.” NTT. Accessed 26 Jun. 2025.
7. He, Qiqi, et al. “From Digital Human Modeling to Human Digital Twin: Framework and Perspectives in Human Factors.” Chinese Journal of Mechanical Engineering. 37:9 (2024).
8. Rubstein, Adrian. “Using Digital Twins To Improve Drug Development and Delivery.” LinkedIn Pulse. 16 Mar. 2023.
9. Li, Xinxiu, et al. “Digital twins as global learning health and disease models for preventive and personalized medicine.” Genome Medicine. 17: 11 (2025).
10. Papachristou, Konstantinos, et al. “Digital Twins’ Advancements and Applications in Healthcare, Towards Precision Medicine.” J. Pers. Med. 14:1101 (2024).
11. Naudet, Yannick, Christoph Stahl, and Marie Gallais. “Preliminary Systemic Model of (Human) Digital Twin.” PETRA ’23. 5–7Jul. 2023, Corfu, Greece.
12. Laubenbacher, R, et al. “Building digital twins of the human immune system: toward a roadmap.” npj Digital Medicine. 5:64 (2022).
13. An, Gary, and Chase Cockrell. “Drug Development Digital Twins for Drug Discovery, Testing and Repurposing: A Schema for Requirements and Development.” Front. Syst. Biol. 19 Jun. 2022.
14. Van Hoojidonk, Richard. “The rise of human digital twins and why we’re — virtually — cloning people.” Accessed 26 Jun. 2025.
15. “Digital Human Twins: The Future of Medical Research.” Animal-Free Science Advocacy. 18 Sep. 2023.
16. Kesari, Ganes. “Meet Your Digital Twin: The Coming Revolution In Drug Development." Forbes. 29 Sep. 2021.